Investigation of the Number of Tests Required for Assaying Plasma Biomarkers Associated with Alzheimer’s Disease Using Immunomagnetic Reduction
Journal
Neurology and Therapy
Date Issued
2021
Author(s)
Liu H.-C.
Chen H.-H.
Ho C.-S.
Chang J.-F.
Lin C.-C.
Hu C.-J.
Yan S.-H.
Sun Y.
Yang S.-Y.
Abstract
Introduction: Concentrations of plasma biomarkers associated with Alzheimer’s disease have been reported to be as low as several tens of picograms/milliliter (pg/ml). However, in assays measuring these biomarkers, it is likely that repeated measurements are necessary to obtain reliable values. Methods: We performed assays as a single test or as duplicate, quadruplicate, fivefold and tenfold repeated tests, on samples spiked with different concentrations of amyloid β 1–40 (Aβ1–40; 1–1000?pg/ml), Aβ1–42 (1–30,000?pg/ml) and total Tau protein (T-Tau; 0.1–1000?pg/ml), with the aim to to calculate the coefficients of variation (CVs). Results: The results demonstrated common changes in the CVs with changes in the number of tests for a given sample: the CVs decreased with increases in the number of tests from one to ten. All CV values were distributed within the range of 0.35 to 15.5%; as such, the CV values were all lower than the acceptable value of 20%. Conclusion: Based on this study, a single assay of Aβ1–40, Aβ1–42 and T-Tau, respectively, provides reliable results in terms of the measurement of that plasma biomarker. ? 2021, The Author(s).
SDGs
Other Subjects
amyloid beta protein; amyloid beta protein[1-40]; amyloid beta protein[1-42]; biological marker; tau protein; aged; Alzheimer disease; Article; blood sampling; brain size; controlled study; female; Geriatric Depression Scale; hippocampus; human; immunomagnetic separation; major clinical study; male; mathematical model; measurement repeatability; mild cognitive impairment; Mini Mental State Examination; neuropsychological test; plasma; protein blood level; volume
Type
journal article